| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update JS Smolen, R Landewé, J Bijlsma, G Burmester, K Chatzidionysiou, ... Annals of the rheumatic diseases 76 (6), 960-977, 2017 | 5721 | 2017 |
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update JS Smolen, RBM Landewé, JWJ Bijlsma, GR Burmester, M Dougados, ... Annals of the rheumatic diseases 79 (6), 685-699, 2020 | 2592 | 2020 |
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs JS Smolen, R Landewé, FC Breedveld, M Dougados, P Emery, ... Annals of the rheumatic diseases 69 (6), 964-975, 2010 | 2379 | 2010 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 2001* | 2021 |
| Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA) M Dougados, M Soubrier, A Antunez, P Balint, A Balsa, MH Buch, ... Annals of the rheumatic diseases 73 (1), 62-68, 2014 | 1005 | 2014 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 616* | 2021 |
| Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR … JL Nam, KL Winthrop, RF van Vollenhoven, K Pavelka, G Valesini, ... Annals of the Rheumatic Diseases 69 (6), 976-986, 2010 | 549 | 2010 |
| Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis MH Buch, JS Smolen, N Betteridge, FC Breedveld, G Burmester, T Dörner, ... Annals of the rheumatic diseases 70 (6), 909-920, 2011 | 515 | 2011 |
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update JS Smolen, RBM Landewé, SA Bergstra, A Kerschbaumer, A Sepriano, ... Annals of the rheumatic diseases 82 (1), 3-18, 2023 | 504 | 2023 |
| Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study RA Evans, H McAuley, EM Harrison, A Shikotra, A Singapuri, M Sereno, ... The Lancet Respiratory Medicine 9 (11), 1275-1287, 2021 | 474 | 2021 |
| Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis P Domingo, I Mur, GM Mateo, M del Mar Gutierrez, V Pomar, N de Benito, ... Jama 326 (6), 499-518, 2021 | 470 | 2021 |
| Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis S Ramiro, C Gaujoux-Viala, JL Nam, JS Smolen, M Buch, L Gossec, ... Annals of the rheumatic diseases 73 (3), 529-535, 2014 | 466 | 2014 |
| Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of … JL Nam, S Ramiro, C Gaujoux-Viala, K Takase, M Leon-Garcia, P Emery, ... Annals of the rheumatic diseases 73 (3), 516-528, 2014 | 405 | 2014 |
| EULAR definition of difficult-to-treat rheumatoid arthritis G Nagy, NMT Roodenrijs, PMJ Welsing, M Kedves, A Hamar, ... Annals of the rheumatic diseases 80 (1), 31-35, 2021 | 315 | 2021 |
| Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool … GH Ibrahim, MH Buch, C Lawson, R Waxman, PS Helliwell Clinical & Experimental Rheumatology 27 (3), 469, 2009 | 307 | 2009 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial PW Horby, G Pessoa-Amorim, L Peto, CE Brightling, R Sarkar, K Thomas, ... Medrxiv, 2021 | 298 | 2021 |
| Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study RA Evans, OC Leavy, M Richardson, O Elneima, HJC McAuley, ... The Lancet Respiratory Medicine 10 (8), 761-775, 2022 | 286 | 2022 |
| Drug-induced interstitial lung disease: a systematic review S Skeoch, N Weatherley, AJ Swift, A Oldroyd, C Johns, C Hayton, A Giollo, ... Journal of clinical medicine 7 (10), 356, 2018 | 284 | 2018 |
| Synovial tissue research: a state-of-the-art review C Orr, E Vieira-Sousa, DL Boyle, MH Buch, CD Buckley, JD Cañete, ... Nature Reviews Rheumatology 13 (8), 463-475, 2017 | 249 | 2017 |
| B cell biomarkers of rituximab responses in systemic lupus erythematosus EM Vital, S Dass, MH Buch, K Henshaw, CT Pease, MF Martin, F Ponchel, ... Arthritis & Rheumatism 63 (10), 3038-3047, 2011 | 249 | 2011 |
